Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. The transcript is about United Airlines. They discuss aircraft orders, capacity, growth, etc. But the key is whether they convey that the individual size of what they land (e.g., aircraft orders, deals) is escalating compared to their own past. Looking through the transcript: They talk about a big aircraft order with Boeing (100 firm 787, options for 100 more, plus 100 incremental 737). But is that presented as part of an upward drift in deal size? They mention "Our aircraft order book is one of our key assets" and "The cost of the flexibility built into the order book, we can also adjust the delivery time line." But they don't compare the size of this order to previous orders in a way that suggests each new order is bigger. They also talk about capacity growth, but that's about their own operations, not about landing larger deals from customers. The question is about the company's own repeatable business: e.g., selling seats, but that's not a deal size escalation. They talk about corporate travel recovery, but not about larger contracts. They mention "United Next" plan with gauge increases, but that's about their own fleet and operations, not about landing larger engagements from customers. They also talk about opening new gates, clubs, etc., but that's internal investment. No mention of successive engagements of the same kind coming in at progressively larger size. They talk about strong demand, but not about the size of individual deals growing. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.